Exudative age-related macular degeneration
Information
- Disease name
- Exudative age-related macular degeneration
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00793923 | Completed | Phase 1/Phase 2 | A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD | January 2008 | December 2012 |
| NCT00913744 | Completed | Phase 2 | Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion | January 2010 | April 2013 |
| NCT01127360 | Completed | Phase 4 | LUCAS (Lucentis Compared to Avastin Study) | March 2009 | August 2014 |
| NCT01157065 | Completed | Phase 2 | Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration | June 2011 | April 2012 |
| NCT01213082 | Completed | Phase 1/Phase 2 | ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD) | September 2010 | January 31, 2017 |
| NCT01304693 | Completed | Phase 1/Phase 2 | ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients | October 2010 | March 2013 |
| NCT01306591 | Completed | N/A | Bevacizumab for Neovascular Age-related Macular Degeneration | January 2008 | December 2010 |
| NCT01404845 | Completed | N/A | Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation | September 2011 | January 2015 |
| NCT01414153 | Completed | Phase 2 | Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD | August 2012 | June 2015 |
| NCT01500915 | Completed | Phase 4 | FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration | November 2010 | July 2012 |
| NCT01526070 | Completed | Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration | January 2012 | July 2014 | |
| NCT01527435 | Completed | Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD) | December 2011 | December 2015 | |
| NCT02355028 | Completed | Phase 2 | LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration | March 3, 2015 | October 18, 2016 |
| NCT02903576 | Completed | Phase 1/Phase 2 | Stem Cell Therapy for Outer Retinal Degenerations | August 2015 | June 2019 |
| NCT03169660 | Completed | Phase 4 | Intravitreal Aflibercept for Submacular Hemorrhage | December 2015 | January 20, 2019 |
| NCT03744806 | Completed | Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD | January 2015 | August 2018 | |
| NCT04138420 | Completed | Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab | January 25, 2017 | October 30, 2017 | |
| NCT04200248 | Completed | Phase 2 | A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration | December 2, 2019 | December 22, 2021 |
| NCT04640272 | Completed | Phase 2 | A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration | November 3, 2020 | December 22, 2021 |
| NCT01796964 | Completed | Phase 2 | Efficacy and Safety Study of ESBA1008 Versus EYLEA® | March 2013 | August 2014 |
| NCT01810042 | Completed | Phase 4 | Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab | October 2010 | February 2013 |
| NCT01849692 | Completed | Phase 2 | ESBA1008 Microvolume Study | June 2013 | January 2015 |
| NCT01950741 | Completed | Phase 4 | Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy | September 2013 | August 2015 |
| NCT02125864 | Completed | Phase 4 | Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept | April 2014 | November 2014 |
| NCT05539235 | Enrolling by invitation | Phase 2/Phase 3 | Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD | November 12, 2018 | August 1, 2024 |
| NCT02348359 | Terminated | Phase 2 | X-82 to Treat Age-related Macular Degeneration | March 16, 2015 | January 12, 2018 |
| NCT02328209 | Unknown status | N/A | Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration | June 2014 | December 2016 |
| NCT01608113 | Unknown status | Long-term Follow-up of Subfoveal Neovascular AMD | September 2011 | ||
| NCT02976194 | Unknown status | Phase 4 | Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy | November 22, 2016 | January 2020 |
| NCT01961414 | Unknown status | Phase 4 | Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910 | October 2013 | July 2016 |
| NCT02089503 | Unknown status | Monocentric Retrospective Observational Study on Patients With Macular Degeneration | March 2014 | December 2014 |